The fat-loss plateau on week six is rarely a willpower problem. It's an endocrine cascade. The GLP-1 + peptide stack from Chapters 3 and 4 is dropping weight, but the body reads sustained caloric deficit as a survival threat — and survival physiology has its own protocol. Thyroid output drops. Reverse T3 rises. Cortisol locks the sympathetic nervous system into overdrive. Sex hormones get sacrificed to keep the stress axis funded. The scale stops moving, and nothing in your injection schedule is "broken" — the system you're not yet supporting is. This chapter installs the second-tier stack that keeps the downstream axes online while Phase 1 + Phase 2 do their work.
What's actually happening at the cellular level
Three downstream axes get hit hardest by a sustained 15–25% caloric deficit:
Thyroid: T4 → T3 conversion collapses. Under nutrient scarcity, the body increases reverse T3 production to block the active T3 hormone at the receptor. Reverse T3 itself has effectively no metabolic activity — practitioner consensus is that you need astronomical levels of rT3 to do anything at the receptor — but its job isn't to act. Its job is to compete with active T3 for the same binding sites and shut metabolism down. The D1 and D2 deiodinase enzymes that convert T4 → active T3 get downregulated; the D3 pathway that converts T4 → rT3 gets upregulated. The thyroid master regulator can drop a person's natural daily burn by 500+ calories without any change in TSH on a standard lab panel — which is why a TSH-only screen misses this entirely.
The substrate is consistent here: pro-inflammatory cytokines, low selenium, low iron, low calories, and elevated cortisol all independently decrease T4 → T3 conversion. Stack three of those and the conversion floor drops out.
Cortisol: chronic elevation directly disrupts insulin signaling. The practitioner corpus describes this as the central weight-loss-resistance mechanism: sustained cortisol disrupts insulin-signaling to muscle tissue, which produces insulin resistance, which produces weight-loss resistance, which produces inflammation, which produces more cortisol. The negative feedback loop that should be reining in norepinephrine and CRH stops working. The HPA axis loses its checks and balances. People wake up at 4 a.m. wired, crash at 2 p.m., and can't drop weight despite 1,400 kcal compliance.
Sex hormones: the body stops making babies under starvation. Testosterone in men holds up to about a 15% deficit without significant loss. Beyond that — particularly with low fat intake or low carb intake — it crashes. The substrate cites a 21% drop in total testosterone on a high-protein/low-carb diet versus a high-carb/low-protein diet, with significantly higher cortisol on the high-protein arm. In women, the sustained deficit produces anovulatory cycles — no ovulation means no corpus luteum, which means no progesterone production for the second half of the cycle. Estrogen drops, progesterone drops harder, and the estrogen:progesterone ratio destabilizes. Mood, sleep, and water retention all swing.
The supporting-axis stack (Phase 1 + Phase 2 layer)
Run this stack alongside the GLP-1 + Phase 1/Phase 2 peptides from the prior chapters. Doses are weight-loss-protocol specific, drawn from the practitioner substrate.
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| Kisspeptin-10 | 50–100 mcg | SubQ | Daily | 🟣 Experimental | Upstream GnRH stimulator. Maintains HPG axis activity during deficit. More physiologic than HCG — pulsatile LH release mirrors natural physiology. |
| Kisspeptin-10 (higher-dose protocol) | 100–300 mcg | SubQ | 2x/day | 🟣 Experimental | Used when HPG support needs to be more aggressive. Less studied at this dose. |
| Gonadorelin | [practitioner corpus thin on specific dose for weight-loss protocol — track and report] | SubQ | Pulsatile preferred | 🟢 Expert | Direct GnRH analog. Pulsatile dosing matches natural physiology better than continuous. Use when Kisspeptin response is partial. |
| HCG (men on TRT or with HPG suppression) | [practitioner corpus thin on weight-loss-context dose — track and report] | SubQ | EOD or on TRT injection days | 🟢 Expert | Maintains testicular function and pregnenolone/DHEA precursor pool. Use if testosterone drops >15% from baseline. |
| Liothyronine (T3 / Cytomel) | [substrate confirms its use to "skip the middleman" when conversion is blocked but does not specify weight-loss-protocol dose — track and report] | Oral | Daily, split AM/midday | 🔵 Clinical (Rx) | Added when reverse T3 is high and conversion is verifiably blocked. Not for everyone — only when D1/D2 conversion is the documented bottleneck. |
| Selenium | 200 mcg | Oral | Daily | 🔵 Clinical | Cofactor for the deiodinase that converts T4 → T3. Cheap, foundational. |
| Iron (if deficient) | Per ferritin status | Oral | Daily | 🔵 Clinical | Iron deficiency independently impairs T4 → T3 conversion. Test ferritin, transferrin saturation. |
| Adequate dietary fat + cholesterol | ≥0.4 g/kg fat | Oral | Daily | 🔵 Clinical | Raw material for steroid hormone production. Cutting fat too low collapses testosterone. |
For women, layer in cycle-aware adjustments rather than running the same protocol across all 28 days. The substrate describes a luteal-phase shift: rising progesterone, declining estrogen — practitioner consensus is to reduce GH secretagogue stack intensity in the luteal phase and lean on BPC-157, Epitalon, and DSIP for sleep and recovery support during that window.
What you should feel
The substrate cites timeline-specific milestones for the supporting axes:
- Weeks 1–2: Sleep onset improves with adequate fat + cortisol management. Morning cortisol slope normalizes (high AM, tapering through day) before any scale movement resumes.
- Weeks 2–4: If Kisspeptin is added, LH pulses re-establish — the substrate describes recorded LH pulses on Kisspeptin "mirroring natural physiology." Morning erections return in men; cycle regularity returns in women whose cycles had gone anovulatory.
- Weeks 3–6: If selenium/iron/fat were the bottleneck, the practitioner corpus describes free T3 climbing back toward upper-quartile-of-range before TSH visibly changes. The scale resumes movement.
What's NOT happening yet
Set these expectations correctly before the user assumes the protocol is failing:
- TSH won't move first. The practitioner corpus is clear that TSH is a lagging indicator. fT3, fT4, and reverse T3 move first. A flat TSH at week 4 is meaningless on its own.
- Cortisol won't drop in days. The HPA axis is a multi-month recalibration. The substrate frames adrenal dysfunction as the result of months-to-years of overdrive — the recovery rhythm is similarly slow.
- Testosterone won't bounce back on Kisspeptin alone if fat intake is too low. Steroid hormones need cholesterol as a substrate. The deficit needs to allow for ≥0.4 g/kg fat or upstream HPG stimulation has nothing to build with.
- Sex hormone normalization is not the goal of this chapter. The goal is preservation under deficit. Optimization comes after the fat-loss intervention is complete and the body is back at energy balance.
- You don't need T3/Cytomel by default. Most users will resolve thyroid conversion with selenium, iron, adequate calories on refeed days, and cortisol management. T3 is the lever you pull when verified labs (high rT3, low fT3, normal TSH) confirm the conversion is the bottleneck — not before.
The research describes this axis collapse as predictable, not personal — track free T3, reverse T3, morning cortisol, and total testosterone at weeks 4 and 8, then adjust.